Otros idiomas CSPC Pharmaceutical Group Limited

Acciones

1093

HK1093012172

Farmacéuticos

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:53 14/07/2026			Variación 5 días	Varia. 1 de enero.
8,110 ^HKD	-0,61 %		-1,46 %	-3,80 %

07/07	La industria farmacéutica acelera sus planes para conquistar el lucrativo mercado de los fármacos adelgazantes	RE
07/07	CSPC Pharma inicia la fase II del ensayo clínico de su fármaco contra la hiperlipidemia mixta	MT

Otros idiomas

07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
07/07	CSPC Pharma Begins Phase II Trial of Mixed Hyperlipidaemia Drug
07/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2070 Injection For Treatment Of Mixed Hyperlipidaemia At First Centre In China
02/07	European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally
02/07	CSPC Pharma Begins Tumor Drug Trial in China
02/07	AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion
02/07	CSPC Pharma's Tumor Drug Gets Breakthrough Therapy Designation in China
02/07	CSPC Pharma Gets Marketing Nod for Anemia Drug in China
02/07	CSPC Pharma Gets China Nod for Trial of Herpes Zoster Vaccine
02/07	CSPC Pharma, AstraZeneca Enter Development Deal for Potential Renal Disease Drug Candidates
02/07	CSPC Pharmaceutical Group Limited Announces Iron Sucrose Injection Receives Marketing Approval
02/07	CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration for Recombinant Herpes Zoster Vaccine to Conduct Clinical Trial
02/07	CSPC Pharmaceutical Group Limited Officially Initiates Phase I Clinical Study of SYH2095 Tablets as Monotherapy or in Combination Regimens for the Treatment of Advanced Malignant Tumours in China
02/07	Chip Wreck Roils Asian Stock Markets
02/07	AstraZeneca signs CSPC China deal for experimental kidney disease drugs
02/07	China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug
02/07	CSPC Pharmaceutical Group Limited and AstraZeneca Enter into Collaboration, Option and License Agreement for the Development of siRNA Drugs
01/07	CSPC Pharmaceutical Begins Lung Cancer Trial in China
30/06	CSPC Pharmaceutical Group Limited Initiates Phase III Clinical Trial of SYS6010 in Combination with Enlonstobart for Adjuvant Treatment of Resected Stage II-IIIB Non-Small Cell Lung Cancer
29/06	Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
26/06	CSPC Pharma Begins Phase III Trial of SYS6010 Combo for Lung Cancer Treatment
22/06	CSPC Pharma Unit Files New Application for Hong Kong Share Listing
18/06	CSPC Pharma's Tumor Drug Gets Trial Nod from US FDA
18/06	CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China
18/06	CSPC Pharma Unit's Marketing Application of Edaglutide Alpha Injection's New Indication Accepted in China